Summary Multidrug resistance phenotypes in human tumours are associated with the overexpression of the 170 kDa P-glycoprotein encoded by the multidrug resistance 1 (MDRI) gene, and also with that of the non-P-glycoprotein-mediated multidrug resistance gene, MRP, which encodes a 190 kDa membrane ATPbinding protein. We Cancer, 58, 860-864, 1994). In this study, we investigated whether chemosensitising agents of P-glycoprotein-mediated multidrug resistance such as verapamil, a biscoclaurine alkaloid (cepharanthine), and a dihydropyridine analogue (NIK250) could also reverse 
The appearance of multidrug-resistant tumours is a serious problem in cancer chemotherapy. The overexpression of a membrane P-glycoprotein (P-gp) with a molecular weight of 170kDa, encoded by the MDRI gene, is often associated with the acquisition of multidrug resistance (MDR) phenotypes (Bradley et al., 1988) . Reduced drug retention in P-gpoverexpressing cells is due to the enhanced active efflux of anti-cancer agents. MDRJ is often overexpressed in various tumours in cancer patients (Goldstein et al., 1989) . However, the expression of the MDRJ-encoded P-gp is not always coupled with the acquisition of MDR in various human tumour cell lines. Cole et al. (1992) have recently isolated a gene named MRP from a doxorubicin-resistant small-cell lung carcinoma cell line with the MDR phenotype (Mirski et al., 1987) . This MRP gene is amplified in some multidrug resistant cell lines (Krishnamachary and Center, 1993; Barrand et al., 1994) . Zaman et al. (1993) have further demonstrated that MRP is 25-fold overexpressed in a non-P-gp small-cell lung cancer cell line, but not in other non-P-gp MDR cell lines derived from non-small-cell lung cancers. The human breast carcinoma cell line MCF7, which is selected for etoposide resistance, and which overexpresses the MRP gene, is resistant to etoposide and doxorubicin, and shows low-level cross-resistance to vincristine and mitoxantrone (Schneider et al., 1994) . Furthermore, Grant et al. (1994) have demonstrated that HeLa cells transfected with an MRP expression vector display an increase in resistance to doxorubicin, vincristine and etoposide, but not to cisplatin. MRP is a member of the ATP-binding cassette (ABC) superfamily transport system proposed by Hyde et al. (1990) , but MRP has minor sequence homology with the P-gp encoded by the human MDR] gene (Cole et al., 1992) . We (Kiue et al., 1990a,b; Kiue et al., 1991; Watanabe et al., 1991) . We also reported that cepharanthine, a bisbenzylisoquinoline biscoclaurine alkaloid, completely overcomes the resistance of multidrug-resistant sublines derived from human KB carcinoma cells (Shiraishi et al., 1987) . NIK250 and other dihydropyridine analogues as well as cepharanthine and verapamil specifically inhibit the photoaffinity labelling of radioactive azidopine to P-gp of membrane vesicles of MDRJ-overexpressing cancer cells, suggesting that they have high affinity for P-gp (Cornwell et al., 1987; Akiyama et al., 1988; Kiue et al., 1990b; Watanabe et al., 1991) . On the other hand, it has been demonstrated that cyclosporin A and its derivatives, as well as verapamil, modify non-P-gp-mediated multidrug resistance, but their chemosensitisation is not effective (Slovak et al., 1988; Cole et al., 1989; Meijer et al., 1991; Barrand et al., 1993 IN157, T98G, IN500 and CCF-STTG1. Resistance to vincristine, etoposide and doxorubicin in T98G and IN500 cells was almost completely reversed when combined with verapamil or NIK250 (Table I) . Combination with cepharanthine partially reversed resistance to these agents in T98G or IN500 cells, whereas drug resistance to vincristine in CCF-STTG1 cells was almost completely reversed when combined with cepharanthine.
The cellular accumulation of vincristine, etoposide and doxorubicin is often reduced in multidrug-resistant cell lines (Kohno et al., 1988; Matsuo et al., 1990) . The reduced accumulation of etoposide appears to be involved in the relatively higher drug resistance of T98G (Abe et al., 1994a) .
The cellular accumulation of this drug was assayed after 30 and 60 min (Figure 3) hand, these reversing agents had no effect on the accumulation of [3H]vincristine in T98G cells (Figure 3 ). The effect of cepharanthine, verapamil and NIK250 on doxorubicin accumulation determined by fluorescence microscopy Doxorubicin accumulation in T98G cells was compared in the presence and absence of modifiers using fluorescence microscopy. Figure 4 shows that doxorubicin accumulation in the nuclei of untreated T98G cells was lower than that in these cells in the presence of NIK250 when incubated for 40 min with doxorubicin. Doxorubicin in the nuclei of T98G cells was almost completely removed after a further incubation for 120 min in the absence of drug (Figure 4a and b) , whereas it remained in the cells when the cells were incubated with NIK250 (Figure 4c and d) . We also observed a similar, but lesser effect, when doxorubicin was combined with verapamil, whereas cepharanthine had almost no effect on doxorubicin accumulation in nuclei (Figure 4e-h cyclosporin A enhance the drug sensitivity of these cells is unlikely to be the result of a direct interaction of these agents with MRP . Interaction of vincristine with its cellular target, possibly tubulin, might increase the cytotoxicity of the chemosensitising agents themselves -NIK250 and verapamil. However, further studies are required to determine whether this effect is closely involved in their reversal of MRP-mediated vincristine resistance. Although MRP appears to be closely involved in the acquisition of multidrug resistance in cancer cells Grant et al., 1994) , the underlying mechanism of MRP-mediated drug resistance still remains unknown. Calcium antagonists such as verapamil, cyclosporins and other resistance modifiers which can efficiently reverse P-gpmediated multidrug resistance in vitro show a weak chemosensitising effect on non-P-gp-mediated multidrug resistance (Slovak et al., 1988; Cole et al., 1989; Meijer et al., 1991) . Barrand et al. (1993) have also demonstrated that cyclosporin A and its analogue, PSC-833, as well as verapamil, induce only a small degree of chemosensitisation to vincristine and doxorubicin in a human large-cell lung cancer cell line overexpressing MRP. In contrast, Cole et al. (1994) have reported the dramatic chemosensitisation by verapamil of cellular sensitivity to vincristine and doxorubicin in cells transfected with a full-length MRP complementary DNA.
The variability of chemosensitisation in various MRPoverexpressing cell lines suggests that the mechanisms by which these reversing agents act may depend upon the cell types involved, but this remains to be determined. A relevant study by Rhodes et al. (1994) has demonstrated that inhibitors of H+-ATPase, such as 7-chloro-4-nitrobenz-2-oxa-1,3-diazole and bufilomycin Al, could modifly non-P-gp-mediated multidrug resistance in human lung cancer cells. It remains to be determined whether or not dihydropyridine analogues inhibit H+-ATPase.
In conclusion, this study demonstrated that accumulation of etoposide and doxorubicin in T98G cells is enhanced by NIK250 or verapamil, but only slightly, if at all, by cepharanthine. These data suggest that both NIK250 and verapamil can modifiy both P-gp-and MRP-mediated drug resistance, but that cepharanthine modifies only that mediated by P-gp.
